Top Markets
#1 Islamic Coin Islamic Coin +154.50%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.91%
#4 MarsCoin MarsCoin +12.77%
#5 Nockchain Nockchain +12.59%
#6 BOOK OF MEME BOOK OF MEME +11.85%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.84%
#8 SkyAI SkyAI +8.96%
#9 Lighter Lighter +8.81%
#10 Monad Monad +8.69%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Classement en actions #27526
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Prix de l'action
$0.343985
Dernière synchronisation: 2024-07-23
Capitalisation boursière
$32.31M
Changement (1 jour)
11.88%
Changement (1 an)
0.00%
Pays
BE
Échange Biocartis Group N.V. (BCART)

Catégorie

Healthcare
Historique du rendement du dividende pour Biocartis Group N.V. (BCART)
Le rendement du dividende (TTM) de Biocartis Group N.V. (symbole boursier : BCART) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Biocartis Group N.V. (BCART) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
0.31%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
0.71%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
0.00%
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
0.00%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
0.00%
US